Tags

Type your tag names separated by a space and hit enter

The polypill to prevent cardiovascular disease: physicians' perspectives.
Curr Opin Cardiol. 2011 Sep; 26(5):438-42.CO

Abstract

PURPOSE OF REVIEW

The term 'polypill' denotes a single-pill combination of drugs for reducing cardiovascular disease events. The 'polypill strategy' refers to making such a pill available to the population based on age (e.g. 55 years) rather than individually as a result of a clinical decision. This review summarizes recent studies describing physicians' perspectives regarding the polypill.

RECENT FINDINGS

Among 58 physicians in Sri Lanka, 86% likely would prescribe a polypill for primary prevention if a large trial showed it reduced the risk of major cardiovascular disease events. A study of 952 US physicians found that 83% likely would prescribe a polypill for high-risk patients and 62% likely would do so for moderate-risk patients. Among physicians in both countries, degree of risk reduction was an important factor in willingness to prescribe. Other factors considered important were side effects and cost. Physicians had low agreement with forgoing risk factor level monitoring in patients taking a polypill. The majority (89%) of US physicians surveyed would not want a polypill available without a prescription.

SUMMARY

Current physician acceptance of the polypill seems moderate to high, at least when considering a clinical approach to its use. As trial publications emerge, it is possible that physician perspectives may evolve toward greater acceptance of a population-health approach to the implementation of a polypill.

Links

Aggregator Full Text

Authors+Show Affiliations

Viera AJ
Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. anthony_viera@med.unc.edu

MeSH

Anti-Inflammatory Agents, Non-SteroidalAntihypertensive AgentsAspirinAttitude of Health PersonnelCardiovascular DiseasesClinical Trials as TopicDrug CombinationsDrug TherapyFolic AcidHematinicsHumansHydroxymethylglutaryl-CoA Reductase Inhibitors

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21730826

Citation

Viera, Anthony J.. "The Polypill to Prevent Cardiovascular Disease: Physicians' Perspectives." Current Opinion in Cardiology, vol. 26, no. 5, 2011, pp. 438-42.
Viera AJ. The polypill to prevent cardiovascular disease: physicians' perspectives. Curr Opin Cardiol. 2011;26(5):438-42.
Viera, A. J. (2011). The polypill to prevent cardiovascular disease: physicians' perspectives. Current Opinion in Cardiology, 26(5), 438-42. https://doi.org/10.1097/HCO.0b013e3283496759
Viera AJ. The Polypill to Prevent Cardiovascular Disease: Physicians' Perspectives. Curr Opin Cardiol. 2011;26(5):438-42. PubMed PMID: 21730826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The polypill to prevent cardiovascular disease: physicians' perspectives. A1 - Viera,Anthony J, PY - 2011/7/7/entrez PY - 2011/7/7/pubmed PY - 2011/12/22/medline SP - 438 EP - 42 JF - Current opinion in cardiology JO - Curr Opin Cardiol VL - 26 IS - 5 N2 - PURPOSE OF REVIEW: The term 'polypill' denotes a single-pill combination of drugs for reducing cardiovascular disease events. The 'polypill strategy' refers to making such a pill available to the population based on age (e.g. 55 years) rather than individually as a result of a clinical decision. This review summarizes recent studies describing physicians' perspectives regarding the polypill. RECENT FINDINGS: Among 58 physicians in Sri Lanka, 86% likely would prescribe a polypill for primary prevention if a large trial showed it reduced the risk of major cardiovascular disease events. A study of 952 US physicians found that 83% likely would prescribe a polypill for high-risk patients and 62% likely would do so for moderate-risk patients. Among physicians in both countries, degree of risk reduction was an important factor in willingness to prescribe. Other factors considered important were side effects and cost. Physicians had low agreement with forgoing risk factor level monitoring in patients taking a polypill. The majority (89%) of US physicians surveyed would not want a polypill available without a prescription. SUMMARY: Current physician acceptance of the polypill seems moderate to high, at least when considering a clinical approach to its use. As trial publications emerge, it is possible that physician perspectives may evolve toward greater acceptance of a population-health approach to the implementation of a polypill. SN - 1531-7080 UR - https://www.unboundmedicine.com/medline/citation/21730826/The_polypill_to_prevent_cardiovascular_disease:_physicians'_perspectives_ L2 - https://doi.org/10.1097/HCO.0b013e3283496759 DB - PRIME DP - Unbound Medicine ER -